editorial

. 2022 Jan 15;20(4):2215–2225. doi: 10.1007/s10311-021-01369-7

Table 2.

Effectiveness of current vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the Delta (B.1.617.2) variant

Vaccine type	SARS-CoV-2 (original)	B.1.617.2 (Delta variant)	References
BNT162b2 (Pfizer)	n = 43,448 Effectiveness rate^a: 95%	n = 15,749 Effectiveness rate^a: 88%	Bernal et al. (2021) Pfizer (2020)
n = 12,330 (0–13 d after two dose) Effectiveness rate^a: 82%^b	Pouwels et al. (2021)
n = 215,577 (≥ 14 d after two doses) Effectiveness rate^a: 80%^b
n = 1,043,289 (≥ 7 d after two doses) Effectiveness rate^a: 93% (within the first month after two doses) Effectiveness rate^a: 53% (≥ 4 months after two doses)	Tartof et al. (2021)
n = 25 Geometric mean neutralization titer^c: 1,105	n = 25 Geometric mean neutralization titer^c: 442	Liu et al. (2021a)
n = 19 Geometric mean neutralization titer^c: 246.8	n = 19 Geometric mean neutralization titer^c: 106.7 (delta-S₁), 123.4 (delta-S₂)	Lustig et al. (2021)
AZD1222 (ChAdOx1 nCoV-19)	n = 32,451 Effectiveness rate^a: 74%	n = 8244 Effectiveness rate^a: 67%	Bernal et al. (2021) Falsey et al. (2021)
n = 49,308 (0–13 d after two dose) Effectiveness rate^a: 71%^b	Pouwels et al. (2021)
n = 330,677 (≥ 14 d after two doses) Effectiveness rate^a: 67%^b
n = 49 Geometric mean neutralization titer^c: 599.4	n = 49 Geometric mean neutralization titer^c: 88.4	Thiruvengadam et al. (2021)
n = 25 Geometric mean neutralization titer^c: 306	n = 25 Geometric mean neutralization titer^c: 71	Liu et al. (2021a)
CoronaVac	n = 1,322 Effectiveness rate^a: 91.25%	n = 89 Effectiveness rate^a: 59% (included both CoronaVac and CNBG vaccines, and most participants were vaccinated with the former)	Li et al. (2021b) SINOVAC (2020)
China National Biotec Group (CNBG)	n is unknown Effectiveness rate^a: 79.34%		CNBG (2020)

Vaccine type

SARS-CoV-2 (original)

B.1.617.2 (Delta variant)

References

BNT162b2 (Pfizer)

n = 43,448

Effectiveness rate^a: 95%

n = 15,749

Effectiveness rate^a: 88%

Bernal et al. (2021)

Pfizer (2020)

n = 12,330

(0–13 d after two dose)

Effectiveness rate^a: 82%^b

Pouwels et al. (2021)

n = 215,577

(≥ 14 d after two doses)

Effectiveness rate^a: 80%^b

n = 1,043,289

(≥ 7 d after two doses)

Effectiveness rate^a: 93%

(within the first month after two doses)

Effectiveness rate^a: 53%

(≥ 4 months after two doses)

Tartof et al. (2021)

n = 25

Geometric mean neutralization titer^c: 1,105

n = 25

Geometric mean neutralization titer^c: 442

Liu et al. (2021a)

n = 19

Geometric mean neutralization titer^c: 246.8

n = 19

Geometric mean neutralization titer^c: 106.7 (delta-S₁), 123.4 (delta-S₂)

Lustig et al. (2021)

AZD1222

(ChAdOx1 nCoV-19)

n = 32,451

Effectiveness rate^a: 74%

n = 8244

Effectiveness rate^a: 67%

Bernal et al. (2021)

Falsey et al. (2021)

n = 49,308

(0–13 d after two dose)

Effectiveness rate^a: 71%^b

Pouwels et al. (2021)

n = 330,677

(≥ 14 d after two doses)

Effectiveness rate^a: 67%^b

n = 49

Geometric mean neutralization titer^c: 599.4

n = 49

Geometric mean neutralization titer^c: 88.4

Thiruvengadam et al. (2021)

n = 25

Geometric mean neutralization titer^c: 306

n = 25

Geometric mean neutralization titer^c: 71

Liu et al. (2021a)

CoronaVac

n = 1,322

Effectiveness rate^a: 91.25%

n = 89

Effectiveness rate^a: 59%

(included both CoronaVac and CNBG vaccines, and most participants were vaccinated with the former)

Li et al. (2021b)

SINOVAC (2020)

China National Biotec Group (CNBG)

n is unknown

Effectiveness rate^a: 79.34%

CNBG (2020)

(a) Effectiveness rates were determined by whether participants, all vaccinated with two doses of the designated vaccine, had COVID-19 infection. (b) Effectiveness rates in B.1.617.2-dominant periods in the United Kingdom. (c) Geometric mean neutralization titers were determined in sera from participants vaccinated with two doses of the designated vaccine